Jenoptik (JEN) German Select VII Conference summary
Event summary combining transcript, slides, and related documents.
German Select VII Conference summary
15 Apr, 2026Conference overview
The seventh Digital German Select Conference featured 11 German companies, each with 30-minute slots for presentations and Q&A, emphasizing interactive participation via chat.
The next digital conference, Austrian Select, was announced for the following week, focusing on Austrian companies.
Strategic vision and market positioning
The company aims to be a global leader in photonics, driving innovation in semiconductor, medical, metrology, and smart mobility sectors, and addressing mega-trends like digitalization, quality manufacturing, healthcare advancements, and urban safety.
Portfolio is aligned to future photonics markets, emphasizing organic growth, operational excellence, and innovation, with OEM businesses generating about two-thirds of revenue.
Strong value proposition through deep customer relationships, joint R&D, and application excellence.
Company strategy and business model
Focused on photonics, with core competencies in optics and lasers, serving OEM customers in semiconductors, medtech, metrology, and smart mobility.
Products are typically integrated into customer machines, not sold directly to consumers.
Business model centers on joint R&D projects, selling solutions over the product lifecycle, and maintaining deep customer relationships.
Nearly 50% of group sales come from the top seven customers, who share R&D and commercial roadmaps.
Latest events from Jenoptik
- 2026 outlook targets profitable growth, led by semi and defense, after a challenging 2025.JEN
Q4 20259 Apr 2026 - 2025 saw lower revenue but improved cash flow, with growth expected to resume in 2026.JEN
Investor presentation25 Mar 2026 - Revenue and earnings up, 2024 guidance confirmed amid robust semiconductor demand.JEN
Q2 20241 Feb 2026 - Revenue and EBITDA rose, but 2025 targets postponed to 2026 amid industry delays.JEN
Q3 202415 Jan 2026 - Revenue and profit fell in H1 2025, with guidance cut amid ongoing global uncertainties.JEN
Q2 20256 Jan 2026 - 2024 saw strong growth and margins, but 2025 outlook is cautious amid persistent uncertainties.JEN
Q4 20243 Dec 2025 - Revenue and EBITDA fell, but free cash flow and order intake improved amid market uncertainty.JEN
Q3 202512 Nov 2025 - Revenue and profit fell, but Biophotonics and cash flow improved; outlook remains cautious.JEN
Q1 20256 Jun 2025 - Record revenue and EBITDA in 2024, led by semiconductor growth, despite market headwinds.JEN
Q4 2024 TU5 Jun 2025